Literature DB >> 26552959

CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.

Clemens Thoma.   

Abstract

Entities:  

Year:  2015        PMID： 26552959     DOI： 10.1038/nrclinonc.2015.207

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.

Authors:  Yayi He; Leslie Rozeboom; Christopher J Rivard; Kim Ellison; Rafał Dziadziuszko; Hui Yu; Caicun Zhou; Fred R Hirsch
Journal:  Med Sci Monit       Date:  2017-03-09

Review 2.  TIM-3, a promising target for cancer immunotherapy.

Authors:  Yayi He; Jie Cao; Chao Zhao; Xuefei Li; Caicun Zhou; Fred R Hirsch
Journal:  Onco Targets Ther       Date:  2018-10-16       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.